BARDA Signs Biodefense Contracts With GSK And Soligenix
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.